Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 5/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.51 |
| ▸ | PTK2B | Q14289 | 1/20 | 0.51 |
| ▸ | MEN1 | O00255 | 3/20 | 0.48 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.48 |
| ▸ | CNR1 | P21554 | 1/20 | 0.47 |
| ▸ | CNR2 | P34972 | 1/20 | 0.47 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.46 |
| ▸ | CA12 | O43570 | 1/20 | 0.46 |
| ▸ | CA1 | P00915 | 1/20 | 0.46 |
| ▸ | CA2 | P00918 | 1/20 | 0.46 |
| ▸ | CA7 | P43166 | 1/20 | 0.46 |
| ▸ | CA9 | Q16790 | 1/20 | 0.46 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.46 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | RECQL | P46063 | 1/20 | 0.45 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6840729 | 0.92 | KMT2A (0.51) | KMT2AALDH1A1PTK2BMEN1CNR1 | |
| SCHEMBL8085939 | 0.90 | MEN1 (0.57) | KMT2AMEN1PTPN1KDM4ERECQL | |
| SCHEMBL9712657 | 0.90 | KMT2A (0.57) | KMT2AALDH1A1PTK2BMEN1HIF1A | |
| SCHEMBL28214715 | 0.89 | LMNA (0.60) | KMT2AALDH1A1MEN1CNR1CNR2 | |
| SCHEMBL5722029 | 0.89 | LMNA (0.60) | KMT2AALDH1A1MEN1CNR1CNR2 | |
| SCHEMBL9153749 | 0.89 | LMNA (0.60) | KMT2AALDH1A1MEN1CNR1CNR2 | |
| SCHEMBL124096 | 0.86 | LMNA (0.55) | KMT2AALDH1A1PTK2BMEN1CA12 | |
| SCHEMBL29225452 | 0.85 | ALDH1A1 (0.53) | KMT2AALDH1A1PTK2BMEN1CA12 | |
| SCHEMBL124950 | 0.84 | ALDH1A1 (0.71) | KMT2AALDH1A1PTK2BMEN1HIF1A | |
| SCHEMBL31643582 | 0.84 | ALDH1A1 (0.71) | KMT2AALDH1A1PTK2BMEN1HIF1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 127 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2739303-B1 | A NOVEL METHOD FOR PERORAL DELIVERY OF INSULIN AND ITS ANALOGUES FOR THERAPEUTIC USAGE | TRANSGENE BIOTEK LTD (IN) | 2020-04-01 | — | — | EP | claimed |
| US-20150051142-A1 | NOVEL METHOD FOR PERORAL DELIVERY OF INSULIN AND ITS ANALOGUES FOR THERAPEUTIC USAGE | TRANSGENE BIOTEK LTD (IN) | 2015-02-19 | — | — | US | claimed |
| EP-2739303-A2 | A NOVEL METHOD FOR PERORAL DELIVERY OF INSULIN AND ITS ANALOGUES FOR THERAPEUTIC USAGE | Transgene Biotek Ltd. (IN) | 2014-06-11 | — | — | EP | claimed |
| WO-2013021346-A2 | A NOVEL METHOD FOR PERORAL DELIVERY OF INSULIN AND ITS ANALOGUES FOR THERAPEUTIC USAGE | TRANSGENE BIOTEK LTD (IN) | 2013-02-14 | — | — | WO | claimed |
| US-20040013734-A1 | Mixture of water insoluble drug and polymer | PFIZER INC. | 2004-01-22 | — | — | US | claimed |
| EP-1027886-A2 | Pharmaceutical solid dispersions | Pfizer Products Inc. (US) | 2000-08-16 | — | — | EP | claimed |
| US-20250281624-A1 | METHODS AND COMPOSITIONS FOR TREATING CHRONIC INFLAMMATORY INJURY, METAPLASIA, DYSPLASIA AND CANCERS OF EPITHELIAL TISSUES | UNIVERSITY OF HOUSTON SYSTEM (US) | 2025-09-11 | — | — | US | disclosed |
| EP-4419104-A2 | METHODS AND COMPOSITIONS FOR TREATING CHRONIC INFLAMMATORY INJURY, METAPLASIA, DYSPLASIA AND CANCERS OF EPITHELIAL TISSUES | University of Houston System (US) | 2024-08-28 | — | — | EP | disclosed |
| CN-118284420-A | Methods and compositions for treating chronic inflammatory lesions, metaplasias, dysplasias, and cancers of epithelial tissue | 休斯敦大学体系 | 2024-07-02 | — | — | CN | disclosed |
| CN-114007671-B | Methods and compositions for treating chronic inflammatory lesions, metaplasias, dysplasias, and cancers of epithelial tissue | 休斯敦大学体系 | 2024-06-14 | — | — | CN | disclosed |
| WO-2023239422-A2 | METHODS AND COMPOSITIONS FOR TREATING CHRONIC INFLAMMATORY INJURY, METAPLASIA, DYSPLASIA AND CANCERS OF EPITHELIAL TISSUES | UNIVERSITY OF HOUSTON SYSTEM (US) | 2023-12-14 | — | — | WO | disclosed |
| US-20230233691-A1 | METHODS AND COMPOSITIONS FOR TREATING CHRONIC INFLAMMATORY INJURY, METAPLASIA, DYSPLASIA AND CANCERS OF EPITHELIAL TISSUES | UNIVERSITY OF HOUSTON SYSTEM (US) | 2023-07-27 | — | — | US | disclosed |
| US-20230149295-A1 | INFLAMMATORY BOWEL DISEASE STEM CELLS, AGENTS WHICH TARGET IBD STEM CELLS, AND USES RELATED THERETO | UNIVERSITY OF HOUSTON SYSTEM (US) | 2023-05-18 | — | — | US | disclosed |
| WO-1996011671-A1 | TARGETED DELIVERY VIA BIODEGRADABLE POLYMERS | FOCAL, INC. (US) | 1996-04-25 | — | — | WO | disclosed |
| EP-0671906-A1 | BIOADHESIVE MICROSPHERES AND THEIR USE AS DRUG DELIVERY AND IMAGING SYSTEMS | BROWN UNIVERSITY RESEARCH FOUNDATION (US) | 1995-09-20 | — | — | EP | disclosed |
| WO-1993021906-A9 | BIOADHESIVE MICROSPHERES AND THEIR USE AS DRUG DELIVERY AND IMAGING SYSTEMS | — | 1994-03-17 | — | — | WO | disclosed |
| US-5286763-A | Polyanhydride and biacative molecular; nontoxic residues | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 1994-02-15 | — | — | US | disclosed |
| WO-1993021906-A1 | BIOADHESIVE MICROSPHERES AND THEIR USE AS DRUG DELIVERY AND IMAGING SYSTEMS | BROWN UNIVERSITY RESEARCH FOUNDATION (US) | 1993-11-11 | — | — | WO | disclosed |
| EP-0476045-A1 | BIOERODIBLE POLYMERS FOR DRUG DELIVERY IN BONE. | MASSACHUSETTS INST TECHNOLOGY (US) | 1992-03-25 | — | — | EP | disclosed |
| WO-1990015586-A2 | BIOERODIBLE POLYMERS FOR DRUG DELIVERY IN BONE | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 1990-12-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250281624-A1 | METHODS AND COMPOSITIONS FOR TREATING CHRONIC INFLAMMATORY INJURY, METAPLASIA, DYSPLASIA AND CANCERS OF EPITHELIAL TISSUES | FABP2, MYADM, FABP6 | KMT2A 3663/4885ALDH1A1 306/4885PTK2B 1606/4885 |
| US-20040013734-A1 | Mixture of water insoluble drug and polymer | ABCG2, ABCB1, ABCB11 | KMT2A 3238/4885ALDH1A1 2151/4885PTK2B 1820/4885 |
| US-20230233691-A1 | METHODS AND COMPOSITIONS FOR TREATING CHRONIC INFLAMMATORY INJURY, METAPLASIA, DYSPLASIA AND CANCERS OF EPITHELIAL TISSUES | FABP2, MYADM, FABP6 | KMT2A 3663/4885ALDH1A1 306/4885PTK2B 1606/4885 |
| US-20230149295-A1 | INFLAMMATORY BOWEL DISEASE STEM CELLS, AGENTS WHICH TARGET IBD STEM CELLS, AND USES RELATED THERETO | EPCAM, FABP2, TPMT | KMT2A 577/4885ALDH1A1 413/4885PTK2B 3922/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.